REFERENCES
1. Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394:1915-28.
2. Burtness B, Rischin D, Greil R, et al. Pembrolizumab alone or with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death ligand-1 combined positive score. J Clin Oncol. 2022;40:2321-32.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Head and Neck Cancers. Version 1. 2022. Available from: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf [Last accessed on 17 May 2023].
4. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Eng J Med. 2016;375:1856-67.
5. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Eng J Med. 2008;359:1116-27.
6. Cohen EEW, Soulières D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393:156-67.
7. Hamid O, Robert C, Hosi FS, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30:582-88.
8. Larkin J, Chiarion-Sileni, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Eng J Med. 2019;181:1535-46.
9. Gettinger S, Horn L, Jackman D, et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: Results from the CA209-003 study. J Clin Oncol. 2018;36:1675-84.
10. Motzer RJ, Escudier B, George S, et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer. 2020;126:4156-67.
11. Ferris RL, Blumenschein GJ, Fayette J, et al. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018;81:45-51.
12. Matsuo M, Yasumatsu R, Masuda M, et al. Five-year follow-up of patients with head and neck cancer treated with nivolumab and long-term responders for over two years. In Vivo. 2022;36:1881-6.
13. Pons-Tostivint E, Latoiche A, Vaflard P, et al. Comparative analysis of durable responses on immune checkpoint inhibitors versus other systemic therapies: a pooled analysis of phase III trials. JCO Precis Oncol. 2019;3:1-10.
14. Gauci ML, Lanoy E, Champiat S, et al. Long-term survival in patients responding to anti-PD-1/PD-L1 therapy and disease outcome upon treatment discontinuation. Clin Cancer Res. 2019;25:946-956.
15. Jansen YJL, Rozeman EA, Mason R, et al. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Ann Oncol. 2019;30:1154-61.
16. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168:707-23.
17. Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 2018;118:9-16.
18. Sato Y, Fukuda N, Fujiwara YU, et al. Efficacy of paclitaxel-based chemotherapy after progression on nivolumab for head and neck cancer. In Vivo. 2021;35:1211-15.
19. Park SE, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM. Increased response rates to salvage chemotherapy administered after PD-1/PD-L1 Inhibitors in patients with non-small cell lung cancer. J Thorac Oncol. 2018;13:106-11.
20. Guigay J, Aupérin A, Fayette J, et al. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2021;22:463-75.
21. Borcoman E, Kanjanapan Y, Champiat S, et al. Novel patterns of response under immunotherapy. Ann Oncol. 2019;30:385-96.
22. Haddad R, Concha-Benavente F, Blumenschein G Jr, et al. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: a subgroup analysis of a randomized phase 3 clinical trial. Cancer. 2019;125:3208-18.
23. Frelaut M, Le Tourneau C, Borcoman E. Hyperprogression under immunotherapy. Int J Mol Sci. 2019;20:2674.
24. Saâda-Bouzid E, Defaucheux C, Karabajakian A, et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2017;28:1605-11.
25. Harrington KJ, Rischin D, Greil R, et al. KEYNOTE-048: progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). JCO. 2020;38:6505-6505.
26. Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2022;20:387-405.
27. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39:4073-126.
28. Saleh K, Daste A, Martin N, et al. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer. 2019;121:123-9.
29. Tahara M, Kiyota N, Yokota T, et al. Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02). Ann Oncol. 2018;29:1004-9.
30. Tsakonas G, Specht L, Kristensen CA, et al. Randomized phase II study with cetuximab in combination with 5-FU and cisplatin or carboplatin vs. cetuximab in combination with paclitaxel and carboplatin for treatment of patients with relapsed or metastatic squamous cell carcinoma of the head and neck (CETMET Trial). Cancers. 2020;12:3110.
31. Wakasaki T, Manako T, Yasumatsu R, et al. Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: a multicenter clinical study. PLoS One. 2022;17:e0271907.
32. Wakasaki T, Yasumatsu R, Masuda M, et al. Prognostic biomarkers of salvage chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma. Cancers. 2020;12:2299.
33. Fushimi C, Okamoto I, Matsuki T, et al. Salvage chemotherapy after nivolumab for recurrent or metastatic head and neck carcinoma. Anticancer Res. 2020;40:5277-83.
34. Pestana RC, Becnel M, Rubin ML, et al. Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol. 2020;101:104523.
35. Kurosaki T, Mitani S, Tanaka K, et al. Safety and efficacy of cetuximab-containing chemotherapy after immune checkpoint inhibitors for patients with squamous cell carcinoma of the head and neck: a single-center retrospective study. Anticancer Drugs. 2021;32:95-101.
36. Ueki Y, Takahashi T, Ota H, Shodo R, Yamazaki K, Horii A. Role of programmed death-ligand 1 in predicting the treatment outcome of salvage chemotherapy after nivolumab in recurrent/metastatic head and neck squamous cell carcinoma. Head Neck. 2020;42:3275-81.
37. Cabezas-Camarero S, Cabrera-Martín MN, Merino-Menéndez S, et al. Safety and efficacy of cetuximab-based salvage chemotherapy after checkpoint inhibitors in head and neck cancer. Oncologist. 2021;26:e1018-35.
38. Wakasugi T, Takeuchi S, Ohkubo JI, Suzuki H. Retreatment with nivolumab for patients with recurrent and/or metastatic head and neck cancer. Acta Otolaryngol. 2022;142:206-12.
39. Payne K, Spruce R, Beggs A, et al. Circulating tumor DNA as a biomarker and liquid biopsy in head and neck squamous cell carcinoma. Head Neck. 2018;40:1598-604.
40. Li T, Li J, Wang H, et al. Exosomes: potential biomarkers and functions in head and neck squamous cell carcinoma. Front Mol Biosci. 2022;9:881794.
41. Takenaka Y, Oya R, Takemoto N, Inohara H. Neutrophil-to-lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: meta-analysis. Head Neck. 2022;44:1237-45.
42. Qian JM, Schoenfeld JD. Radiotherapy and immunotherapy for head and neck cancer: current evidence and challenges. Front Oncol. 2020;10:608772.
43. Tsushima N, Shinozaki T, Fujisawa T, et al. Salvage reconstructive surgery during nivolumab therapy for a patient with hypopharyngeal cancer. Clin Med Insights Case Rep. 2020;13:1179547620908854.
44. Choi JS, Sansoni ER, Lovin BD, et al. Abscopal effect following immunotherapy and combined stereotactic body radiation therapy in recurrent metastatic head and neck squamous cell carcinoma: a report of two cases and literature review. Ann Otol Rhinol Laryngol. 2020;129:517-22.
45. Whiteside TL, Demaria S, Rodriguez-Ruiz ME, Zarour HM, Melero I. Emerging opportunities and challenges in cancer immunotherapy. Clin Cancer Res. 2016;22:1845-55.
46. Sharabi AB, Lim M, DeWeese TL, Drake CG. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 2015;16:e498-509.
47. Mohiuddin TM, Zhang C, Sheng W, et al. Near infrared photoimmunotherapy: a review of recent progress and their target molecules for cancer therapy. Int J Mol Sci. 2023;24:2655.
48. Dymova MA, Taskaev SY, Richter VA, Kuligina EV. Boron neutron capture therapy: current status and future perspectives. Cancer Commun. 2020;40:406-21.
